Retrospective side effect profiling of the metastatic melanoma combination therapy Ipilimumab-Nivolumab using adverse event data

Recent studies suggest that combining nivolumab with ipilimumab is a more effective treatment for melanoma patients, compared to using ipilimumab or nivolumab alone. However, treatment with these immunotherapeutic agents is frequently associated with increased risk of toxicity, and (auto-) immune-re...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Soldatos, Theodoros (VerfasserIn) , Dimitrakopoulou-Strauss, Antonia (VerfasserIn) , Larribere, Lionel (VerfasserIn) , Hassel, Jessica C. (VerfasserIn) , Sachpekidis, Christos (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 31 October 2018
In: Diagnostics
Year: 2018, Jahrgang: 8, Heft: 4
ISSN:2075-4418
DOI:10.3390/diagnostics8040076
Online-Zugang:Verlag, Volltext: https://doi.org/10.3390/diagnostics8040076
Verlag, Volltext: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6316083/
Volltext
Verfasserangaben:Theodoros G. Soldatos, Antonia Dimitrakopoulou-Strauss, Lionel Larribere, Jessica C. Hassel, Christos Sachpekidis

MARC

LEADER 00000caa a2200000 c 4500
001 1685935540
003 DE-627
005 20220817193848.0
007 cr uuu---uuuuu
008 191218s2018 xx |||||o 00| ||eng c
024 7 |a 10.3390/diagnostics8040076  |2 doi 
035 |a (DE-627)1685935540 
035 |a (DE-599)KXP1685935540 
035 |a (OCoLC)1341286643 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Soldatos, Theodoros  |e VerfasserIn  |0 (DE-588)1201773377  |0 (DE-627)1685935990  |4 aut 
245 1 0 |a Retrospective side effect profiling of the metastatic melanoma combination therapy Ipilimumab-Nivolumab using adverse event data  |c Theodoros G. Soldatos, Antonia Dimitrakopoulou-Strauss, Lionel Larribere, Jessica C. Hassel, Christos Sachpekidis 
264 1 |c 31 October 2018 
300 |a 13 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 18.12.2019 
520 |a Recent studies suggest that combining nivolumab with ipilimumab is a more effective treatment for melanoma patients, compared to using ipilimumab or nivolumab alone. However, treatment with these immunotherapeutic agents is frequently associated with increased risk of toxicity, and (auto-) immune-related adverse events. The precise pathophysiologic mechanisms of these events are not yet clear, and evidence from clinical trials and translational studies remains limited. Our retrospective analysis of ~7700 metastatic melanoma patients treated with ipilimumab and/or nivolumab from the FDA Adverse Event Reporting System (FAERS) demonstrates that the identified immune-related reactions are specific to ipilimumab and/or nivolumab, and that when the two agents are administered together, their safety profile combines reactions from each drug alone. While more prospective studies are needed to characterize the safety of ipilimumab and nivolumab, the present work constitutes perhaps the first effort to examine the safety of these drugs and their combination based on computational evidence from real world post marketing data. 
700 1 |a Dimitrakopoulou-Strauss, Antonia  |d 1963-  |e VerfasserIn  |0 (DE-588)1076688373  |0 (DE-627)835256901  |0 (DE-576)167486055  |4 aut 
700 1 |a Larribere, Lionel  |e VerfasserIn  |0 (DE-588)1118655079  |0 (DE-627)872164837  |0 (DE-576)479578648  |4 aut 
700 1 |a Hassel, Jessica C.  |d 1975-  |e VerfasserIn  |0 (DE-588)129790702  |0 (DE-627)480399069  |0 (DE-576)29783715X  |4 aut 
700 1 |a Sachpekidis, Christos  |d 1983-  |e VerfasserIn  |0 (DE-588)1099707269  |0 (DE-627)858738651  |0 (DE-576)469338482  |4 aut 
773 0 8 |i Enthalten in  |t Diagnostics  |d Basel : MDPI, 2011  |g 8(2018,4) Artikel-Nummer 76, 13 Seiten  |h Online-Ressource  |w (DE-627)718627814  |w (DE-600)2662336-5  |w (DE-576)365413917  |x 2075-4418  |7 nnas  |a Retrospective side effect profiling of the metastatic melanoma combination therapy Ipilimumab-Nivolumab using adverse event data 
773 1 8 |g volume:8  |g year:2018  |g number:4  |g extent:13  |a Retrospective side effect profiling of the metastatic melanoma combination therapy Ipilimumab-Nivolumab using adverse event data 
856 4 0 |u https://doi.org/10.3390/diagnostics8040076  |x Verlag  |x Resolving-System  |3 Volltext 
856 4 0 |u https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6316083/  |x Verlag  |3 Volltext 
951 |a AR 
992 |a 20191218 
993 |a Article 
994 |a 2019 
998 |g 1099707269  |a Sachpekidis, Christos  |m 1099707269:Sachpekidis, Christos  |d 910000  |d 911400  |e 910000PS1099707269  |e 911400PS1099707269  |k 0/910000/  |k 1/910000/911400/  |p 5  |y j 
998 |g 129790702  |a Hassel, Jessica C.  |m 129790702:Hassel, Jessica C.  |d 910000  |d 911300  |e 910000PH129790702  |e 911300PH129790702  |k 0/910000/  |k 1/910000/911300/  |p 4 
998 |g 1118655079  |a Larribere, Lionel  |m 1118655079:Larribere, Lionel  |d 60000  |d 61900  |e 60000PL1118655079  |e 61900PL1118655079  |k 0/60000/  |k 1/60000/61900/  |p 3 
998 |g 1076688373  |a Dimitrakopoulou-Strauss, Antonia  |m 1076688373:Dimitrakopoulou-Strauss, Antonia  |d 910000  |d 911400  |e 910000PD1076688373  |e 911400PD1076688373  |k 0/910000/  |k 1/910000/911400/  |p 2 
999 |a KXP-PPN1685935540  |e 3566681148 
BIB |a Y 
SER |a journal 
JSO |a {"physDesc":[{"extent":"13 S."}],"recId":"1685935540","relHost":[{"physDesc":[{"extent":"Online-Ressource"}],"recId":"718627814","disp":"Retrospective side effect profiling of the metastatic melanoma combination therapy Ipilimumab-Nivolumab using adverse event dataDiagnostics","origin":[{"dateIssuedDisp":"2011-","dateIssuedKey":"2011","publisherPlace":"Basel","publisher":"MDPI"}],"pubHistory":["1.2011 -"],"language":["eng"],"type":{"bibl":"periodical","media":"Online-Ressource"},"note":["Gesehen am 28.05.2020"],"id":{"issn":["2075-4418"],"eki":["718627814"],"zdb":["2662336-5"]},"part":{"year":"2018","extent":"13","volume":"8","text":"8(2018,4) Artikel-Nummer 76, 13 Seiten","issue":"4"},"title":[{"subtitle":"open access journal","title":"Diagnostics","title_sort":"Diagnostics"}]}],"person":[{"role":"aut","given":"Theodoros","family":"Soldatos","display":"Soldatos, Theodoros"},{"family":"Dimitrakopoulou-Strauss","role":"aut","given":"Antonia","display":"Dimitrakopoulou-Strauss, Antonia"},{"display":"Larribere, Lionel","family":"Larribere","role":"aut","given":"Lionel"},{"role":"aut","given":"Jessica C.","family":"Hassel","display":"Hassel, Jessica C."},{"family":"Sachpekidis","given":"Christos","role":"aut","display":"Sachpekidis, Christos"}],"origin":[{"dateIssuedKey":"2018","dateIssuedDisp":"31 October 2018"}],"note":["Gesehen am 18.12.2019"],"type":{"media":"Online-Ressource","bibl":"article-journal"},"language":["eng"],"title":[{"title_sort":"Retrospective side effect profiling of the metastatic melanoma combination therapy Ipilimumab-Nivolumab using adverse event data","title":"Retrospective side effect profiling of the metastatic melanoma combination therapy Ipilimumab-Nivolumab using adverse event data"}],"name":{"displayForm":["Theodoros G. Soldatos, Antonia Dimitrakopoulou-Strauss, Lionel Larribere, Jessica C. Hassel, Christos Sachpekidis"]},"id":{"eki":["1685935540"],"doi":["10.3390/diagnostics8040076"]}} 
SRT |a SOLDATOSTHRETROSPECT3120